68,919 Shares in AstraZeneca PLC $AZNCF Purchased by Smith Salley Wealth Management

Smith Salley Wealth Management acquired a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 68,919 shares of the company’s stock, valued at approximately $13,592,000.

Other large investors also recently bought and sold shares of the company. Evolve Private Wealth LLC purchased a new position in AstraZeneca during the first quarter worth about $511,000. Meadowbrook Advisors Group LLC acquired a new stake in shares of AstraZeneca during the first quarter valued at about $371,000. Center For Asset Management LLC purchased a new stake in shares of AstraZeneca in the 1st quarter valued at approximately $398,000. Vaughan Nelson Investment Management L.P. purchased a new stake in shares of AstraZeneca in the 1st quarter valued at approximately $2,042,000. Finally, Balboa Wealth Partners acquired a new position in shares of AstraZeneca in the 1st quarter worth approximately $238,000. Institutional investors and hedge funds own 40.87% of the company’s stock.

AstraZeneca Price Performance

OTCMKTS:AZNCF opened at $187.10 on Monday. The company has a 50 day moving average price of $187.10 and a 200 day moving average price of $186.05. AstraZeneca PLC has a fifty-two week low of $122.26 and a fifty-two week high of $195.00.

AstraZeneca Company Profile

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.